Rexlemestrocel-l shows greatest treatment benefit on major adverse cardiovascular events in high-risk heart failure patients with diabetes and/or myocardial ischemia

Endpoint in line with fda guidance on key outcomes in high-risk patients and with pharma industry drugs approved for cardiovascular risk reduction in diabetes endpoint in line with fda guidance on key outcomes in high-risk patients and with pharma industry drugs approved for cardiovascular risk reduction in diabetes
MESO Ratings Summary
MESO Quant Ranking